Inserm Transfer Initiative featured in the first round for VectivBio, a short bowel syndrome treatment developer spun out of Therachon following the latter's acquisition by Pfizer.
VectivBio, a Switzerland-based rare disease therapy developer, on Tuesday launched with $35m in capital from backers including Inserm Transfer Initiative, the investment arm of research institute Inserm.
Pharmaceutical firm Novo also participated, as did government-owned investment bank Bpifrance, financial services firm Cowen’s Healthcare Investments unit, investment fund Tekla Healthcare Investors and VC firms Versant Ventures and OrbiMed.
VectivBio is developing treatments for a range of serious rare diseases. Its lead asset, Apraglutide, targets short bowel syndrome (SBS), caused…
